WARNINGS

The patients with the depressive riot importing (MDD), so grown-up as of paediatrics, can know
fact to deteriorate of their depression and/or appearance of ideation suicide and of behaviour
(suicidality) or unusual changes in behaviour, if indeed they take the antidepressant
treatments and this risk can keep until significant delivery occurs. The suicide is a known risk
depression and some of other psychiatric riot and this riot themselves are the strongest prophets of suicide. There was a longstanding concern, however, it antidepressants can have a role in fact to encourage deteriorating of depression and of appearance of suicidality in some patients during the first stages of treatment.
Analyses pooled of in the short term trials controlled by the placebo of medicaments of antidepressant (SSRIS and others) showed that these medicaments augment the risk of suicidal reflexion and of behaviour (Suicidality) at the children, the teenagers and the young adults ages 18-24) with the depressive riot importing (MDD) and other psychiatric riot.
Short-term studies did not show increase in risk of suicidality with antidepressants compared with the placebo in the adults beyond age 24; there was a reduction with antidepressants compared with the placebo in the old adults 65 and older. Analyses pooled by trials controlled by the placebo at the children and the teenagers with MDD, maniacal compulsive riot (OCD), or other psychiatric riot included a total of 24 in the short term the trials of 9 medicaments of antidepressant in more than 4400 patients.
Analyses pooled by placebocontrolled trials in the adults with MDD or other psychiatric riot included a total of 295 in the short term trials (the medium length of 2 months) of 11 medicaments of antidepressant in more than 77 000 patients.
There was considerable variation in risk of suicidality among medicaments, but a tendency towards one the increase in the younger patients for almost all medicaments studied. There was difference in absolute risk of suicidality across different indications, with the highest impact in MDD.

No suicide occurred in any of the trials of paediatrics. There were suicides in grown-up trials, but
the number was not sufficient to attain any conclusion of the effect of medicament on the suicide.

It is unknown if risk of suicidality stretches in the long-term use, that is to say, beyond several
month. However, there is the substantial obviousness of the trials of maintenance controlled by the placebo in the adults with depression that the use of antidepressants can postpone the recurrence of depression.

All patients being treated with antidepressants for any indication should be controlled
properly and noticed nearly for fact to damage private hospital, suicidality and unusual changes
in behaviour, especially during some initial months of a course of therapy of medicament, or in
the time of changes of dose, increase or reductions.